{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:30:42Z","timestamp":1773369042414,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["3R01DA048533-02S1"],"award-info":[{"award-number":["3R01DA048533-02S1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["3R01DA048533-02S1"],"award-info":[{"award-number":["3R01DA048533-02S1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["3R01DA048533-02S1"],"award-info":[{"award-number":["3R01DA048533-02S1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30 DA035772"],"award-info":[{"award-number":["P30 DA035772"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30 DA035772"],"award-info":[{"award-number":["P30 DA035772"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s11606-021-07174-w","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T21:02:17Z","timestamp":1635454937000},"page":"162-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Initiating Opioid Use Disorder Medication via Telemedicine During COVID-19: Implications for Proposed Reforms to the Ryan Haight Act"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-3956","authenticated-orcid":false,"given":"Haiden A.","family":"Huskamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Uscher-Pines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisa B.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pushpa","family":"Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ateev","family":"Mehrotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"7174_CR1","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https:\/\/www.samhsa.gov\/data\/;2020."},{"key":"7174_CR2","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences E, Medicine","year":"2019","unstructured":"National Academies of Sciences E, Medicine. Medications for Opioid Use Disorder Save Lives. Washington: The National Academies Press; 2019."},{"key":"7174_CR3","unstructured":"Dooling BCE, Stanley L. Extending Pandemic Flexibilities for Opioid Use Disorder Treatment: Telemedicine & Initiating Buprenorphine Treatment. 2021; https:\/\/regulatorystudies.columbian.gwu.edu\/extending-pandemic-flexibilities-opioid-use-disorder-treatment. Accessed May 11, 2021."},{"issue":"1","key":"7174_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2020.3940","volume":"324","author":"L Uscher-Pines","year":"2020","unstructured":"Uscher-Pines L, Huskamp HA, Mehrotra A. Treating Patients With Opioid Use Disorder in Their Homes: An Emerging Treatment Model. JAMA. 2020;324(1):39-40.","journal-title":"JAMA."},{"issue":"1","key":"7174_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1056\/NEJMp1813961","volume":"380","author":"CS Davis","year":"2019","unstructured":"Davis CS. The SUPPORT for Patients and Communities Act - What Will It Mean for the Opioid-Overdose Crisis? N Engl J Med. 2019;380(1):3-5.","journal-title":"N Engl J Med."},{"key":"7174_CR6","unstructured":"Congress.gov. H.R.6 - SUPPORT for Patients and Communities Act, 115th Congress (2017-2018). https:\/\/www.congress.gov\/bill\/115th-congress\/house-bill\/6. Accessed August 11, 2021."},{"key":"7174_CR7","unstructured":"WebMD Medscape. Market Research 2020; https:\/\/www.medscape.com\/sites\/public\/marketresearch. Accessed May 11, 2021."},{"key":"7174_CR8","unstructured":"Mezher M. FDA to Survey Healthcare Professionals on Prescription Drug Marketing. 2019; https:\/\/www.raps.org\/news-and-articles\/news-articles\/2019\/3\/fda-to-survey-healthcare-professionals-on-prescrip. Accessed May 11, 2021."},{"key":"7174_CR9","unstructured":"U.S. Food and Drug Administration. Office of Pharmaceutical Quality: 2019 Annual Report February 2020."},{"key":"7174_CR10","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.15585\/mmwr.mm6738a2","volume":"67","author":"CL Black","year":"2018","unstructured":"Carla L. Black, Xin Yue, Sarah W. Ball, et al. Influenza Vaccination Coverage Among Health Care Personnel \u2014 United States, 2017\u201318 Influenza Season. MMWR Morb Mortal Wkly Rep. 2018;67:1050\u20131054.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"7174_CR11","unstructured":"Locke T. Nearly 1 in 3 on Front Line Lacked PPE: Medscape UK COVID-19 Poll. Medscape. May 19, 2020. https:\/\/www.medscape.com\/viewarticle\/930736. Accessed 11 May 2021"},{"issue":"11","key":"7174_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1176\/appi.ps.202000250","volume":"71","author":"L Uscher-Pines","year":"2020","unstructured":"Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett ML, Huskamp HA. Suddenly Becoming a \"Virtual Doctor\": Experiences of Psychiatrists Transitioning to Telemedicine During the COVID-19 Pandemic. Psychiatr Serv. 2020;71(11):1143-1150.","journal-title":"Psychiatr Serv."},{"key":"7174_CR13","doi-asserted-by":"publisher","first-page":"108124","DOI":"10.1016\/j.jsat.2020.108124","volume":"118","author":"L Uscher-Pines","year":"2020","unstructured":"Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett M, Huskamp HA. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat. 2020;118:108124.","journal-title":"J Subst Abuse Treat."},{"issue":"3","key":"7174_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/add.14436","volume":"114","author":"CM Jones","year":"2019","unstructured":"Jones CM, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2019;114(3):471-482.","journal-title":"Addiction."},{"key":"7174_CR15","doi-asserted-by":"publisher","first-page":"102905","DOI":"10.1016\/j.drugpo.2020.102905","volume":"93","author":"CS Davis","year":"2020","unstructured":"Davis CS, Samuels EA. Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19. Int J Drug Policy. 2020:93:102905.","journal-title":"Int J Drug Policy."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-07174-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-021-07174-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-07174-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:11:44Z","timestamp":1666915904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-021-07174-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["7174"],"URL":"https:\/\/doi.org\/10.1007\/s11606-021-07174-w","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflict of Interest","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Barnett reports being retained as an expert witness for government plaintiffs in lawsuits against opioid manufacturers and distributors. The authors have no other potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}